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Abstract
Background: Several arenaviruses cause severe hemorrhagic fever and aseptic meningitis in humans for which no 
licensed vaccines are available. A major obstacle for vaccine development is pathogen heterogeneity within the 
Arenaviridae family. Evidence in animal models and humans indicate that T cell and antibody-mediated immunity play 
important roles in controlling arenavirus infection and replication. Because CD4+ T cells are needed for optimal CD8+ T 
cell responses and to provide cognate help for B cells, knowledge of epitopes recognized by CD4+ T cells is critical to 
the development of an effective vaccine strategy against arenaviruses. Thus, the goal of the present study was to 
define and characterize CD4+ T cell responses from a broad repertoire of pathogenic arenaviruses (including 
lymphocytic choriomeningitis, Lassa, Guanarito, Junin, Machupo, Sabia, and Whitewater Arroyo viruses) and to provide 
determinants with the potential to be incorporated into a multivalent vaccine strategy.
Results: By inoculating HLA-DRB1*0101 transgenic mice with a panel of recombinant vaccinia viruses, each expressing 
a single arenavirus antigen, we identified 37 human HLA-DRB1*0101-restricted CD4+ T cell epitopes from the 7 
antigenically distinct arenaviruses. We showed that the arenavirus-specific CD4+ T cell epitopes are capable of eliciting 
T cells with a propensity to provide help and protection through CD40L and polyfunctional cytokine expression. 
Importantly, we demonstrated that the set of identified CD4+ T cell epitopes provides broad, non-ethnically biased 
population coverage of all 7 arenavirus species targeted by our studies.
Conclusions: The identification of CD4+ T cell epitopes, with promiscuous binding properties, derived from 7 different 
arenavirus species will aid in the development of a T cell-based vaccine strategy with the potential to target a broad 
range of ethnicities within the general population and to protect against both Old and New World arenavirus infection.
Background
Several arenaviruses within the Arenaviridae family are
rodent-borne human pathogens. Infection outcomes can
range from subclinical disease to central nervous system
damage [1], aseptic meningitis [2], congenital deformities
[3,4], and severe hemorrhagic fever (reviewed in [5]).
Mortality among patients with arenaviral hemorrhagic
fever ranges from 15 to 30% [6,7]. Accordingly, arenavirus
infections are considered a serious human public health
problem. Despite the pathogenicity of arenaviruses, there
are no licensed vaccines available and the live attenuated
Junin virus (JUNV) vaccine, Candid #1, only has investi-
gational new drug status in the U.S. [8]. Moreover, antivi-
ral therapies are limited to the use of hyperimmune
plasma [1] or the guanosine analogue ribavirin, which can
l e a d  t o  a d v e r s e  s i d e  e f f e c t s  s u c h  a s  t h r o m b o c y t o s i s ,
severe anemia, and birth defects [9,10]. Because of their
pathogenicity and the lack of vaccines and antivirals to
prevent and treat infection, arenaviruses are also
regarded as a potential bioterrorism threat, and as such
are classified as Class A pathogens. Thus, there is a need
to develop novel prophylactic vaccination strategies to
combat arenavirus infection.
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Several studies have reported a beneficial role for both
T cell and antibody-mediated immunity in countering
arenavirus infections. Vaccine strategies aimed at gener-
ating a CD8+ T cell-mediated response confer protection
against virus challenge in murine [11-14], guinea pig
[15,16], and non-human primate [17] models of infection
of two Old World arenaviruses, Lassa virus (LASV) and
lymphocytic choriomeningitis virus (LCMV). In humans,
cell-mediated immunity also seems to be critical for pro-
tection against LASV infection, as neutralizing antibodies
appear several weeks or months after viral clearance
[18,19], and treatment of infected patients with hyperim-
mune plasma does not protect against disease [20]. In
contrast, antibody-mediated immunity seems to play an
important role protecting against New World arenavirus
infection, as administration of immune plasma at an early
infection stage significantly reduces morbidity and mor-
tality [21]. T cell responses might also be involved in
countering New World arenavirus infection as, similar to
LASV infection, neutralizing antibodies often appear sev-
eral weeks after resolution of infection of the New World
arenavirus, JUNV [22]. JUNV-specific T cell responses
have also been detected in patients vaccinated with Can-
did #1 [8].
An important component in developing protective
CD8+ T cell and antibody-mediated immunity is the gen-
eration of effective CD4+ T cell help. Several previous
studies, conducted in murine models of LCMV infection,
have demonstrated that virus-specific CD4+ T cells play
an essential role in priming optimal CD8+  T cell
responses in vivo. Infection of mice lacking CD4+ T cells
(either by transient depletion or knock-out) with LCMV
Armstrong led to the failure of LCMV-specific CD8+ T
cells to expand upon antigen re-encounter, thus demon-
strating that CD4+ T cell help is required for secondary
memory CTL expansion during acute virus infection
[23]. In mouse models of chronic LCMV infection, it has
long been established that CD4+ T cell help is required to
control viremia [24,25]. However, it was recently demon-
strated that IL-21, produced by antigen-specific CD4+ T
cells, is the critical helper factor needed to sustain effec-
tor CD8+  T cell activity and contain viremia during
chronic LCMV infection [26-28]. In addition to providing
help, in the case of LCMV infection, CD4+ T cells have
been shown to have direct effector function mediated by
cytokine secretion and cytolytic activity [29].
Given the importance of CD4+ T cells, a critical step in
the development of a vaccine strategy against arenavi-
ruses is the definition of arenavirus-specific CD4+ T cell
epitopes with the capacity to induce help. However, one
of the major obstacles in designing an arenavirus vaccine
is the genetic diversity found amongst the different mem-
bers of the Arenaviridae family, as well as the variability
within a single arenavirus species. To overcome this chal-
lenge, it might be possible to combine antigens or
epitopes derived from several arenavirus species in the
same vaccine, and thus provide effective multivalent pro-
tection.
Thus, the goal of the present study was to identify HLA
class II-restricted CD4+ T cell epitopes derived from are-
naviruses associated with disease in humans that have the
competency to provide help in a vaccination setting. We
specifically targeted the 4 viral proteins (glycoprotein
precursor (GPC), RNA-dependent RNA polymerase (L),
nucleocapsid protein (NP), and zinc-finger binding pro-
tein (Z)) that are encoded by the 7 different species,
including Guanarito virus (GTOV), JUNV, LASV, LCMV,
Machupo virus (MACV), Sabia virus (SABV), and White-
water Arroyo virus (WWAV). Because of the high degree
of HLA class II polymorphism expressed in the human
population, we focused on defining HLA-DRB1*0101-
restricted CD4+ T cell epitopes, as these epitopes have
demonstrated broad reactivity with other HLA-DR mole-
cules [30], and thus have the potential to provide exten-
sive population coverage across different ethnicities ([31]
and J. Sidney and A. Sette, unpublished observations).
Here, we tested whether it was possible to define HLA-
DRB1*0101-restricted CD4+ T cell responses from the 7
arenaviruses of interest that provide broad population
coverage, and demonstrate a polyfunctional phenotype
with the potential to impart help.
Results
Identification of HLA-DRB1-restricted arenavirus CD4+ T cell 
epitopes
Recent studies have defined a large number of HLA class
I-restricted CD8+ T cell epitopes derived from GTOV,
JUNV, LASV, LCMV, MACV, SABV, and WWAV
[11,12,14]. By contrast, very few human arenavirus-spe-
cific epitopes recognized by CD4+ T cells, and restricted
by HLA class II, have been described. To identify arenavi-
rus-specific CD4+ T cell epitopes, the common HLA-DR
supertype specificity HLA-DRB1*0101 was selected, as
HLA-DRB1*0101-restricted epitopes tend to also be
broadly reactive with other HLA-DRB1, DRB3, DRB4,
and DRB5 molecules, and thus have the potential to pro-
vide broad coverage across a highly diverse human popu-
lation [31]. Accordingly, 3772 peptides, corresponding to
15-mer peptides overlapping by 10 amino acids and span-
ning the GPC, L, NP, and Z consensus protein sequences
from the 7 target arenavirus species, were screened for
their capacity to bind HLA-DRB1*0101. Using this
approach, a total of 299 high affinity (50% inhibitory con-
centration; IC50 ≤ 50 nM) HLA-DRB1*0101 binding pep-
tides were identified (Table 1 and data not shown).Kotturi et al. Immunome Research 2010, 6:4
http://www.immunome-research.com/content/6/1/4
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Table 1: Summary of characteristics of arenavirus-derived HLA-DRB1*0101-restricted CD4+ T cell epitopes.
Epitopea Sequence DRB1*0101 binding 
affinity
(IC50 nM)b
ELISPOT
(net SFC/106 CD4+)c
ICS
(%IFN-γ+ CD4+)d
GTOV GPC131-145 KGSPEFDWILGWTIK 1.7 208 0.22
GTOV L181-195 DQEYHRLIHSLSKTS 0.34 390 0.05
GTOV L391-405 RVLDILVARRLLLKK 0.19 330 0.11
GTOV L1826-1840 IQLVFSSMINPLVIT 0.23 163 0.04
GTOV NP166-180 KLNNQFGSMPALTIA 0.12 122 0.05
GTOV NP191-205 NNVVQALTSLGLLYT 0.29 97 0.05
GTOV NP236-250 ISGYNFSLSAAVKAG 0.12 126 0.03
GTOV NP541-555 IPIQLLPNTLVFQAK 0.25 142 0.11
JUNV GPC46-60 FFVFLALAGRSCTEE 0.23 684 0.06
JUNV L381-395 VGQMLMLVNDRLLDI 0.21 323 0.06
JUNV L391-405 RLLDILEAIKLIRKK 0.48 333 0.08
JUNV L411-425 KWVQMCSRTLKNSHQ 1.1 571 0.05
JUNV L1491-1505 MFIRNCARKVFNDIK 2.0 425 0.11
JUNV L1711-1725 NKNFFWAVKPKAVRQ 0.06 538 0.16
LASV GPC236-250 PSPIGYLGLLSQRTR 0.14 497 0.07
LASV GPC241-255 YLGLLSQRTRDIYIS 0.29 469 0.05
LASV GPC476-490 SCGLYKQPGVPVRWK 1.5 273 0.04
LCMV GPC421-435 LRKDYIKRQGSTPLA 4.8 268 0.16
LCMV L256-270 RNFQKVNPEGLIKEF 5.6 217 0.07
LCMV L946-960 HLRKVILSEISFHLV 2.1 533 0.07
LCMV NP6-20 EVKSFQWTQALRREL 49 436 0.07
LCMV NP521-535 MDCIIFESASKARLP 4.4 463 0.12
MACV GPC96-110 NSFYYMKGGVNTFLI 0.21 365 0.08
MACV GPC251-265 SKTHLNFERSLKAFF 1.7 427 0.12
MACV GPC446-460 ASLFLHLVGIPTHRH 0.13 329 0.08
MACV L391-405 DRVLDILEAVKLIRK 0.48 423 0.22
MACV L636-650 RYFLMAFANQIHHID 0.24 269 0.06
MACV L866-880 DYLILKNLTGLVSAG 0.21 322 0.13
MACV L1491-1505 TSFIRNCARKVFNDI 0.11 400 0.07
MACV L1711-1725 NNQNFFWAVKPKVVR 1.7 518 0.09
MACV NP191-205 NSVVQALTSLGLLYT 0.78 176 0.06
MACV Z21-35 PSAEFRRTAPPSLYG 2.0 313 0.16
SABV GPC26-40 VSLIAALKGMINLWK 0.47 264 0.04
SABV GPC436-450 FTTTLFLHLVGFPTH 0.92 1213 0.08
SABV GPC441-455 FLHLVGFPTHRHIRG 0.09 823 0.05
WWAV GPC46-60 FIVFLLLAGRSCSYK 1.2 701 0.10
WWAV GPC386-400 FRNQWLLESDHLISE 1.6 517 0.39
a Peptide position within the GPC, L, NP, or Z protein of prototypic strains of GTOV, JUNV, LASV, LCMV, MACV, SABV, and WWAV.
b Each epitope was tested for binding to HLA-DRB1*0101.
c Peptide tested at 10 μg/ml in IFN-γ ELISPOT assays. Criteria for positivity are net SFC/106 cells ≥ 20, SI ≥ 1.4, and p-value ≤ 0.05 in two or more 
independent assays. Average IFN-γ responses are shown from two independent experiments.
d Peptide tested at 3 μg/ml in IFN-γ ICS assays. The epitope-specific responses were calculated by subtracting the total number of cells that 
scored positive for IFN-γ+ production in the absence of peptide. Criterion for positivity is SI ≥ 2.0 in two or more independent assays. Average 
IFN-γ responses are shown from two independent experiments.Kotturi et al. Immunome Research 2010, 6:4
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Because human PBMC samples from arenavirus-
exposed individuals were difficult to obtain, HLA-
DRB1*0101 transgenic mice were used to identify human
arenavirus epitopes [32]. To determine the in vivo antige-
nicity of the 299 peptides, HLA-DRB1*0101 transgenic
mice were primed with a recombinant vaccinia virus
(rVACV) expressing one of the arenavirus proteins and
subsequently boosted with peptide pools emulsified in
incomplete Freund's adjuvant (IF A) as described in the
Methods. Mice were not infected with the native arenavi-
ruses because the majority of arenaviruses studied
require biosafety level-4 (BSL-4) containment. Inocula-
tion of mice with the rVACV constructs still enabled the
identification of endogenously processed CD4+  T cell
epitopes. Eleven to 14 days after peptide immunization,
purified splenic CD4+ T cells were screened for recogni-
tion of the arenavirus peptides through IFN-γ ELISPOT
assays (Table 1 and data not shown).
To demonstrate that the observed responses were CD4+
T cell-specific, we subsequently tested the ELISPOT pos-
itive peptides in IFN-γ intracellular cytokine staining
(ICS) assays. These assays also provided a quantitative
estimate of the frequency of responding arenavirus-spe-
cific CD4+ T cells. In total, 37 out of the 299 high affinity
binding peptides were antigenic in both IFN-γ ELISPOT
and ICS assays, with averaged responses ranging from
0.03 to 0.39% IFN-γ-producing CD4+ T cells. Figure 1
shows representative responses for each of the 37 CD4+ T
cell epitopes that induced a positive IFN-γ response with
a SI ≥ 2. Minor recognition of 4 out of 37 epitopes (GTOV
NP236-250, GTOV L1826-1840, LCMV L946-960, and MACV
GPC96-110) by CD8+  T cells was observed (data not
shown), suggesting that these 15-mer peptides might also
contain nested CD8+ T cell epitopes. The sequences of
the 37 CD4+ T cell epitopes identified, along with the cor-
responding viral antigen, the HLA-DRB1*0101 binding
affinity, and the averaged IFN-γ ELISPOT and ICS
responses, are summarized in Table 1. An average of 5
epitopes (ranging from 2 to 10) were defined from each of
the arenavirus species. The average binding affinity (IC50)
of the 37 epitopes to HLA-DRB1*0101 was 0.72 nM,
while the average IC50 of the remaining 262 non-epitopes
was 0.96 nM. The difference between the two sets of pep-
tides was not statistically significant, thus demonstrating
that high binding affinity alone does not define a T cell
epitope. Overall, these data demonstrate that the CD4+ T
cell epitope set provides broad coverage of the 7 different
arenaviruses of interest, suggesting their potential to be
incorporated into a multivalent arenavirus vaccine strat-
egy.
Arenavirus-specific CD4+ T cells have a polyfunctional 
phenotype
Polyfunctional CD4+ T cell responses have been corre-
lated with optimal protection against infection in vivo
[33,34]. Because of the importance of IFN-γ, TNF-α, and
IL-2 in mediating protection, we examined the frequency
of IFN-γ, TNF-α, and IL-2 expressing CD4+ T cells elic-
ited by a representative subset of the HLA-DRB1*0101-
restricted epitopes derived from the GPC, L, and NP pro-
teins of LCMV (LCMV GPC421-435, L946-960, or NP6-20,
respectively). In these experiments, splenic CD4+ T cells
were derived from HLA-DRB1*0101 transgenic mice that
were primed with a rVACV expressing either the LCMV
GPC, L, or NP and boosted with a single peptide emulsi-
fied in complete Freund's adjuvant (CFA). CFA was uti-
lized in the peptide immunization mixture to expand
antigen-specific CD4+ T cell subsets to detectable fre-
quencies for the FACS analysis.
Utilizing multiparameter ICS assays, we quantified the
fraction of the total cytokine response comprised of 3,
any 2, or any 1 cytokine in response to in vitro stimula-
tion with either the LCMV GPC421-435, L946-960, or NP6-20
epitope. We found that the different LCMV-specific
epitopes induced similar cytokine expression patterns.
Three cytokines were produced by 30 to 40% of cytokine-
expressing CD4+ T cells, a little over half expressed any 2
cytokines, and ~10% produced any 1 cytokine (Figure
2A).
Next, we measured the frequency of CD4+  T cells
expressing the different combinations of cytokines (Fig-
ure 2B, LCMV GPC421-435 shown as representative data).
We detected 6 out of the 7 possible cytokine combina-
tions, but the vast majority of CD4+ T cells were IFN-
γ+TNF-α+IL-2+ and IFN-γ+TNF-α+. To a lesser extent,
IFN-γ+IL-2+, TNF-α+IL-2+, single IFN-γ+, and single
TNF-α+  producing CD4+  T cells were also detected.
Although LCMV GPC421-435 is shown as representative
data, the majority of CD4+  T cells restimulated with
either the LCMV L946-960 or the NP6-20 peptide also were
IFN-γ+TNF-α+IL-2+ and IFN-γ+TNF-α+ (Figure 2A and
data not shown). Thus, these data show that the arenavi-
rus-specific CD4+ T cell epitopes are capable of eliciting
T cells primarily with a polyfunctional phenotype.
Interaction between CD40 and its ligand, CD40L
(expressed by activated CD4+ T cells), is a key mediator in
the priming of antigen-specific CD8+ T cells [35-37] and
B cells [38]. Thus, to further characterize the LCMV-spe-
cific CD4+ T cells, we measured the frequency of cells
expressing CD40L. In these experiments, splenic CD4+ T
cells were derived from HLA-DRB1*0101 transgenic mice
that were primed with a rVACV expressing either theKotturi et al. Immunome Research 2010, 6:4
http://www.immunome-research.com/content/6/1/4
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Figure 1 Identification of antigenic arenavirus-derived CD4+ T cell epitopes in HLA-DRB1*0101 transgenic mice. Groups of HLA-DRB1*0101 
transgenic mice were inoculated with a rVACV expressing a single arenavirus antigen, and 7 days later, immunized with an appropriate pool of GTOV, 
JUNV, LASV, LCMV, MACV, SABV, or WWAV peptides. Positive peptides in IFN-γ ELISPOT assays were tested in ICS assays using splenocytes from immu-
nized HLA-DRB1*0101 mice as described in Materials and Methods. The numbers indicate the percent of CD4+ T cells producing IFN-γ following stim-
ulation with 3 μg/ml of each of the listed peptides. A peptide was considered positive if the response was ≥ 2 SI above background in two 
experiments. Representative data from at least two independent experiments is shown.
CD4
I
F
N
-
 .24
GTOV GPC131-145
.09
GTOV NP541-555
.07
GTOV NP166-180
GTOV NP191-205
.05
GTOV NP236-350
.04
GTOV L181-195
.07
GTOV L1826-1840
.05
GTOV L391-405
.11
JUNV GPC46-60
.07
JUNV L411-425
.05 .12
JUNV L1491-1505 JUNV L1711-1725
.14
JUNV L391-405
.06
JUNV L381-395
.11
No peptide
.01
MACV GPC446-460
.11
MACV GPC96-110
.07
MACV GPC251-265
.16
MACV NP191-205
.06
MACV L391-405
.21
MACV L866-880
.14
MACV L1711-1725
.10
.10
MACV L1491-1505
MACV Z21-35
.18
SABV GPC441-455
.06
SABV GPC436-450
.10
SABV GPC26-40
.05
.14
WWAV GPC46-60
.41
WWAV GPC386-400
MACV L636-650
.08
LASV GPC236-250
.06
LASV GPC241-255
.05
LASV GPC476-490
.04
LCMV GPC421-435
.17
LCMV NP521-535
.14
LCMV L256-270
.08
LCMV NP6-20
.08 .11
LCMV L946-960Kotturi et al. Immunome Research 2010, 6:4
http://www.immunome-research.com/content/6/1/4
Page 6 of 14
LCMV GPC, L, or NP and boosted with the correspond-
ing peptide emulsified in CFA. Following in vitro peptide
restimulation, we found that the LCMV GPC421-435, L946-
960, and NP6-20  epitopes induced robust expression of
CD40L (Figure 3), indicating the competency of these
CD4+ T cell subsets to provide help.
Arenavirus CD4+ T cell epitopes degenerately bind to 
additional HLA-DR molecules
P r e v i o u s  w o r k  h a s  e s t a b l i s h e d  t h a t  e p i t o p e s  w i t h  t h e
capacity to bind with high affinity to HLA-DRB1*0101
tend to also be broadly reactive with other HLA-DRB1,
DRB3, DRB4, and DRB5 molecules, and thus have the
ability to provide extensive population coverage across
different ethnicities ([30,31] and J. Sidney and A. Sette,
unpublished observations). As the HLA-DR supertype
consists of a group of molecules that share largely over-
lapping peptide binding specificities, we tested the bind-
ing affinity of the 37 arenavirus-specific CD4+ T cell
epitopes to 14 common HLA-DRB1, DRB3, DRB4, and
DRB5 molecules, as described in Materials and Methods.
The number of allelic molecules bound is summarized in
Figure 2 Arenavirus-specific CD4+ T cells have a polyfunctional phenotype. Epitope-specific cytokine production (IFN-γ, TNF-α, and IL-2) from 
splenic CD4+ T cells of a group of three rVACV primed and peptide boosted HLA-DRB1*0101 transgenic mice was measured 11 to 14 days after peptide 
immunization. (A) The fraction of the total cytokine response comprising LCMV GPC421-435, L946-960, or NP6-20-specific CD4+ T cells expressing all 3 cy-
tokines, any 2 cytokines, or any 1 cytokine. (B) The frequency of LCMV GPC421-435-specific CD4+ T cells expressing each of the seven possible combina-
tions of IFN-γ, TNF-α, and IL-2. Results from one experiment are shown and are representative of at least two independent experiments. Error bars 
indicate SEM.
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Table 2. The 37 different arenavirus-specific CD4+ T cell
epitopes bound, on average, 8 different HLA-DR mole-
cules (range 2 to 13). These data demonstrate that the
HLA-DRB1*0101-restricted epitopes extensively bind to
several HLA-DR molecules, suggesting that these
e p i t o p e s  h a v e  t h e  c a p a c i t y  t o  p r o v i d e  r e l a t i v e l y  b r o a d
coverage across different ethnic populations.
Broadly reactive HLA-DR-restricted arenavirus CD4+ T cell 
epitopes provide widespread population coverage
Next, based on the capacity of each CD4+ T cell epitope
to bind different common HLA-DR molecules, we esti-
mated the breadth of population coverage afforded by
this epitope set. Here, we defined coverage as the extent
or degree to which different ethnic populations world-
wide recognize the CD4+ T cell epitope set. A high degree
of coverage suggests that the epitope set might also be
able to provide broad protection against a variety of are-
n a v i r u s e s .  T o  e s t i m a t e  p o p u l a t i o n  c o v e r a g e ,  w e  c a l c u -
lated the theoretical coverage in various populations
afforded by the CD4+ T cell epitopes for each of the 7 are-
naviruses using the Population Coverage Calculation
Tool available through the Immune Epitope Database and
Analysis Resource [39]. Because allele frequency data for
the HLA-DRB3, DRB4, and DRB5 loci are not available,
these calculations are based on the HLA-DRB1 allele fre-
quencies alone, and thus likely represent conservative
estimates. For the present analysis, biologically relevant
binding was defined as an IC50 ≤ 200 nM.
The total coverage of the general population provided
by the corresponding set of epitopes for each of the 7 dif-
ferent arenaviruses is shown in Figure 4A. In this case,
coverage is shown as an average across 11 different popu-
lation groups characterized by the Database of MHC [40].
The epitopes identified from GTOV, JUNV, and MACV
provided the broadest population coverage, with 92.3% of
the overall population recognizing at least one or more
epitope(s), while WWAV epitopes provided the least
amount of coverage (63.9%). The remaining viruses,
LASV, LCMV, and SABV provided 76.3%, 85.0%, and
76.3% population coverage, respectively. When averaged
over the 7 different viruses, the defined epitopes provided
population coverage of 82.6% of the entire population. It
is important to note that coverage typically entailed rec-
ognition of multiple HLA-epitope combinations. For
example, from Figure 4A, it can be seen that in an average
population, about 35% of individuals can be expected to
recognize 6 or more HLA-epitope combinations. Thus,
this analysis suggests that the defined epitopes provide
not only wide-ranging coverage, but also an appreciable
degree of redundant coverage, which may be important
in the context of RNA viruses with high mutation rates.
The coverage provided by the epitope panel was also
reasonably balanced throughout the major ethnic groups.
As representative data, Figure 4B shows the coverage
afforded by the GTOV-specific CD4+  T cell epitopes
across several major population groups. As shown, the
GTOV epitopes provide coverage ranging from about
67.7% of South Americans, to 99.7% for Europeans, with
an average coverage across all ethnic populations of
92.3%. The depth of coverage is exemplified by the fact
that, on average, over 80% of the individuals in the gen-
eral population would be expected to present 5 or more
HLA-epitope combinations. These data provide a proof
Figure 3 Arenavirus-specific CD4+ T cells express CD40L. Splenic CD4+ T cells from rVACV primed and peptide boosted HLA-DRB1*0101 transgen-
ic mice were stimulated with the indicated peptides (LCMV GPC421-435, L946-960, or NP6-20), and stained for intracellular IFN-γ and CD40L. Plots are gated 
on CD4+ T cells and the numbers indicate the frequency of cells expressing IFN-γ and CD40L. Results are representative of at least two independent 
experiments.
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LASV GPC236-250 729
LASV GPC241-255 718
LASV GPC476-490 112
LCMV GPC421-435 628
LCMV L256-270 314
LCMV L946-960 83 1 1
LCMV NP6-20 729
LCMV NP521-535 527
MACV GPC96-110 314
MACV GPC251-265 82 1 0
MACV GPC446-460 213
MACV L391-405 718
MACV L636-650 1 031 3
MACV L866-880 729
MACV L1491-1505 93 1 2
MACV L1711-1725 819
MACV NP191-205 82 1 0
MACV Z21-35 82 1 0
SABV GPC26-40 729
SABV GPC436-450 516
SABV GPC441-455 718
WWAV GPC46-60 516
WWAV GPC386-400 628
a Peptide position within the GPC, L, NP, or Z protein of prototypic strains of GTOV, JUNV, LASV, LCMV, MACV, SABV, and WWAV.
b Each epitope was tested for binding to 14 common HLA molecules within the DR supertype. The number of HLA molecules bound 
corresponds to the epitope having an IC50 ≤ 200 nM to the specific HLA molecule.
c The number of DRB3*0101, DRB4*0101, and DRB5*0101 molecules bound by the arenavirus epitopes with an IC50 ≤ 200 nM.Kotturi et al. Immunome Research 2010, 6:4
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Figure 4 The identified arenavirus-specific CD4+ T cell epitopes provide broad population coverage. The theoretical population coverage was 
calculated based on the binding affinity data for each HLA-DRB1-restricted epitope and the reported frequencies of each HLA-DRB1 allele in different 
ethnic populations. Biologically relevant binding was defined as an IC50 ≤ 200 nM. (A) The average population coverage for each of the 7 arenaviruses. 
The horizontal dashed line indicates that 82.6% of the population, on average, recognizes one or more arenavirus epitope. (B) For GTOV, shown as 
representative data, the number of possible peptide-HLA allele combinations as a function of the fraction of each ethnic population (%) is shown. The 
horizontal dashed line represents the fraction of individuals (92.3%) that recognize one or more GTOV peptide in an average population.
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of concept validation that a CD4+ T cell epitope set can be
defined, affording broad coverage across different patho-
genic arenavirus species and multiple HLA class II mole-
cules.
Discussion
Prior to this study, little was known about human arena-
virus-specific CD4+ T cells. To our knowledge, only 6
human CD4+ T cell epitopes derived from a single arena-
virus species, LASV, had been previously described
[41,42]. These earlier studies relied on identifying
epitopes from T cell clones generated from LASV anti-
body (Ab) positive individuals. Because PBMC from are-
navirus-immune donors were not available, we utilized
HLA-DRB1*0101 transgenic mice to carry out an exten-
sive screen of 299 arenavirus-derived peptides that bound
with high affinity to HLA-DRB1*0101. Furthermore, we
bypassed the requirement for BSL-4 containment for
most arenavirus species considered by developing a panel
of 24 rVACV vectors that expressed the different arenavi-
rus antigens of interest. Utilizing this strategy, we identi-
fied 37 different CD4+ T cell epitopes from 7 pathogenic
arenavirus species. Two of these epitopes (GTOV NP191-
205 and MACV NP191-205) overlapped with the ortholo-
gous LASV NP190-202 epitope defined with T cell clones
from LASV-immune individuals [41], suggesting that our
approach identified CD4+ T cell epitopes relevant for
humans. In the future, we plan to examine CD4+ T cell
responses in arenavirus-immune human donors in order
to assess the degree of overlap between arenavirus-spe-
cific responses recognized in HLA transgenic mice and
humans. However, it has been demonstrated with other
infectious pathogens, such as Mycobacterium tuberculo-
sis, that HLA class II transgenic mice recognize the same
pathogen-derived T cell epitopes as humans [43,44].
Given that CD4+ T cells are essential for maintaining
effective CTL responses during an arenavirus infection
[23], knowledge of human CD4+ T cell epitopes is a cru-
cial step in the development of an arenavirus vaccine that
induces effective T cell-mediated immunity. As it is not
likely that separate vaccines for each arenavirus species
will be generated, one strategy might be the development
of a multivalent vaccine that targets multiple species
within the Arenaviridae family. This approach has proven
itself in the case of the currently licensed vaccines against
Streptococcus pneumoniae (i.e. Pneumovax 23), which
contains capsular polysaccharide antigens from 23 of the
most prevalent pneumococcal serotypes [45], and human
papillomavirus (i.e. Gardasil), which consists of capsid
proteins derived from 4 different serotypes prominently
associated with disease [46].
Herein, we defined a set of CD4+ T cell epitopes from 7
different arenaviruses, with promiscuous binding charac-
teristics. Together, these epitopes afforded ~83% cover-
age of the general population, on average, and thus, could
be incorporated into a multivalent vaccine targeting mul-
tiple arenavirus species and ethnicities. For our analyses,
we have excluded coverage at the HLA-DRB3, DRB4, and
DRB5 loci, and also used a conservative threshold of 200
nM to define biologically relevant binding. Previously, we
have shown that over 90% of known HLA-DR epitopes
have an affinity < 1000 nM [30]. Thus, our coverage may
represent a low estimate.
In similar studies, we described the identification of a
collection of human class I-restricted CD8+  T cell
epitopes derived from the same 7 arenaviruses that
afforded 60% coverage of the general population
[11,14,47]. When immunized as a peptide cocktail, the
CD8+ T cell epitopes protected HLA transgenic mice
against challenge with rVACVs expressing either Old or
New World arenavirus GPC [14]. It is tempting to specu-
late that combining arenavirus-specific CD4+ and CD8+ T
cell epitopes into a single multivalent vaccine might
enhance the protective capacity of the CD8+  T cell
response. Furthermore, we showed previously that cross-
reactive T cell recognition of orthologous peptides
derived from different arenavirus species further
increased the coverage afforded by the CD8+  T cell
epitopes. Likewise, we defined several CD4+  T cell
epitopes that shared orthologous sequences between two
or more arenavirus species (i.e. JUNV/WWAV GPC46-60,
GTOV/JUNV/MACV L391-405, JUNV/MACV L1491-1505,
JUNV/MACV L1711-1725, and GTOV/MACV NP191-205),
suggesting the potential for CD4+ T cell cross-reactivity
in vivo, and thus even greater virus and population cover-
age.
Three of the CD4+ T cell responses identified in this
study, (MACV Z21-35, JUNV GPC46-60, and WWAV
GPC46-60), were directed against regions that contained
nested human CD8+ T cell epitopes. Our previous study
defined a HLA-A*1101-restricted epitope, MACV Z27-36,
and a HLA-A*0201-restricted epitope, WWAV GPC42-50
[14]. Overlapping murine CD4+ and CD8+ T cell epitopes
have been described in both H-2b and H-2d mice infected
with LCMV [48-50], and influenza virus infection of H-2b
mice [51]. Thus, it seems that epitope sharing between
both murine and human CD4+ and CD8+ T cells might be
a general phenomenon amongst viruses with small pro-
teomes. These overlapping epitopic regions could be of
particular importance when designing a multivalent vac-
cine strategy that targets both arenavirus-specific CD4+
and CD8+ T cell responses.
The ability of T cell-based vaccine candidates to induce
protective immunity against infection has largely been
associated with the capacity of antigen-specific CD4+ andKotturi et al. Immunome Research 2010, 6:4
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CD8+  T cells to produce multiple effector functions
simultaneously (reviewed in [52]). A recent study evaluat-
ing the protective efficacy of vaccine formulations against
Leishmania major found that vaccine-elicited protection
was best correlated with the concurrent release of IFN-γ,
TNF-α, and IL-2 by antigen-specific CD4+ T cells [33].
Similarly, several studies have demonstrated a strong
association between the maintenance of highly polyfunc-
tional T cell responses and non-progressive HIV infec-
tion [53-55]. Here, we showed that a substantial
percentage of the LCMV-specific CD4+ T cells produced
a polyfunctional response, characterized by simultaneous
release of IFN-γ, TNF-α, and IL-2, following peptide
stimulation. Finally, we demonstrated that the LCMV-
specific CD4+ T cells expressed CD40L following peptide
stimulation, indicating their propensity to provide CD8+
T cell help [35-37]. Taken together, these data suggest
that the identified CD4+ T cell epitopes might help induce
a protective cell-mediated immune response in a vaccina-
tion setting.
Conclusions
In conclusion, the identification of CD4+ and CD8+ T cell
epitopes from 7 different arenavirus species might lead to
the development of a T cell-based vaccine strategy pro-
tecting against Old and New World arenavirus infection
responsible for hemorrhagic fever and aseptic meningitis
in humans. Promiscuous epitopes with the capacity to
bind to multiple alleles within a HLA supertype are of
particular relevance in generating a vaccine that targets a
broad range of ethnicities within the general population.
The validation of both CD4+ and CD8+ T cell epitopes in
arenavirus-immune individuals, and their formulation in
a multivalent construct would also be the logical next
steps in the further exploration of this concept.
Methods
Peptide synthesis
Peptides were synthesized as crude material by Pepscan
Systems (Lelystad, The Netherlands). Candidate epitopes
were resynthesized by A and A Labs (San Diego, CA) and
purified to 95% or greater homogeneity by reverse-phase
HPLC. The IEDB submission identification number for
HLA-DRB1*0101-restricted arenavirus-specific CD4+ T
cell epitopes is 1000404.
MHC peptide-binding assay
Quantitative assays to measure the binding affinity of
peptides to purified HLA-DRB1*0101, DRB1*0301,
DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701,
DRB1*0802, DRB1*0901, DRB1*1101, DRB1*1302,
DRB1*1501, DRB3*0101, DRB4*0101, and DRB5*0101
molecules were based on the inhibition of binding of a
radiolabeled standard peptide, and were performed
essentially as described elsewhere [31,56]. Briefly, after a
2-day incubation, binding of the radiolabeled peptide to
the corresponding MHC class II molecule was deter-
mined by capturing MHC/peptide complexes on Greiner
Lumitrac 600 microplates (Greiner Bio-One, Monroe,
NC) coated with the L243 Ab (anti-DRA), and measuring
bound cpm using the Topcount microscintillation coun-
ter (Packard Instrument). The concentration of peptide
yielding 50% inhibition of the binding of the radiolabeled
probe peptide (IC50) was then calculated. Peptides were
typically tested at 6 different concentrations covering a
100,000-fold dose range, and in 3 or more independent
assays. Under the conditions utilized, where [label] <
[MHC] and IC50 ≥ [MHC], the measured IC50 values are
reasonable approximations of the KD values.
Mice
HLA-DRB1*0101 transgenic mice on a FVB/N back-
ground [32] were crossed with C57BL/6J Aβ° mice to
generate animals on a C57BL/6J background with no
endogenous mouse MHC class II. HLA-DRB1*0101 Aβ°
transgenic mice (referred to as HLA-DRB1*0101)
retained the expression of mouse MHC class I. Mice were
bred and maintained in the animal facilities at the La Jolla
Institute for Allergy and Immunology (La Jolla, CA). All
mouse studies followed guidelines set by the National
Institutes of Health and the Institutional Animal Care
and Use Committee-approved animal protocols (Associa-
tion for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC# 000840) and
Office of Laboratory Animal Welfare (OLAW# A3779-
01)).
Viruses and immunizations
rVACV were generated as previously described [14], and
are available from the Biodefense and Emerging Infec-
tions Research Resources Repository (BEI Resources;
http://www.beiresources.org; BEIR NR-15486-NR-15509)
[57]. In total, 24 different rVACV were constructed, each
expressing a single arenavirus protein, either the GPC, L,
NP, or Z protein. rVACV expressing the JUNV Z, SABV
L,  W W A V  L,  a n d  W W A V  Z  w e r e  n o t  g e n e r a t e d ,  a n d
therefore, peptides derived from these viral proteins were
not tested for antigenicity in mice. Groups of three HLA-
DRB1*0101 transgenic mice were injected i.p. with 107
PFU rVACV, as this infectious dose has been routinely
used in previous studies [11,14,47]. Seven days after
rVACV inoculation, mice were peptide-immunized s.c. at
the base of the tail with a pool of 4 to 6 peptides (15 μg/
peptide), or 15 μg of a single peptide in PBS emulsified in
IFA or CFA, respectively. The immunized peptides corre-
sponded to the arenavirus protein expressed by the
rVACV used to inoculate the mice. On day 11 to 14 post-
peptide immunization, mice were sacrificed and splenicKotturi et al. Immunome Research 2010, 6:4
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CD4+ T cells were analyzed by ex vivo ELISPOT and ICS
assays for cytokine production.
IFN-γ ELISPOT assay
The mouse IFN-γ ELISPOT assay was performed as pre-
viously described [58]. In brief, 2 × 105 splenic CD4+ T
cells purified by anti-CD4 magnetic beads [Miltenyi Bio-
tec, Auburn, CA] from immunized HLA-DRB1*0101
transgenic mice were cultured with 105 peptide-pulsed
CD11c+ dendritic cells (DC). Anti-CD11c magnetic beads
(Miltenyi Biotec) were used to purify CD11c+ DCs from
HLA-DRB1*0101 transgenic mice immunized s.c. 12 days
prior with 106  B16 cells expressing fms-like tyrosine
kinase 3 ligand. For peptide pulsing, DCs were incubated
with 10 μg/ml peptide for at least 1 h at 37°C, followed by
3 washes to remove excess peptide. Each assay was per-
formed in triplicate wells. After a 20 h incubation at 37°C,
plates were developed, and responses calculated as
described [58]. Criteria for positivity were net spot-form-
ing cells (SFC)/106 cells ≥ 20, stimulation index (SI) ≥ 1.4,
and p-value ≤ 0.05 using a Student's t test in at least 2 out
of 3 experiments.
Multiparameter ICS assay
Splenocytes from immunized HLA-DRB1*0101 trans-
genic mice were cultured in the presence of 3 μg/ml of
arenavirus peptide and 1 μl/ml Golgiplug (containing
Brefeldin A; BD Biosciences, San Diego, CA) in complete
RPMI medium. After 5-6 h, cells were harvested and
stained for cell surface antigens CD4 and CD8. After
washing, cells were fixed, permeabilized, and stained for
IFN-γ, TNF-α, IL-2, and CD40L using a Cytofix/Cytop-
erm kit, according to manufacturer's directions (BD Bio-
sciences). Approximately 500,000 viable lymphocytes per
sample were acquired on a BD LSR II flow cytometer. The
frequency of CD4+ T cells responding to each arenavirus
peptide was quantified by determining the total number
of gated CD4+ and cytokine+ cells using FlowJo software
(Tree Star, San Carlos, CA).
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